Clb1 Activators
Clb1 Activators consist of a diverse array of chemical compounds that indirectly augment Clb1's activity by modulating various cellular and biochemical pathways. Purvalanol A, Roscovitine, and Olomoucine are selective CDK inhibitors that, by inhibiting CDKs not complexed with Clb1, preferentially enhance the role of Clb1-CDKs in cell cycle progression. Clb1 activators are chemicals that are designed to engage with and enhance the activity of Clb1, a cyclin protein in yeast cells that is crucial for cell cycle progression. Clb1, in conjunction with its cyclin-dependent kinase (CDK) partner, forms a complex that is essential for the initiation of various cell cycle events, including DNA replication and mitosis. The activators of Clb1 can facilitate the formation of this complex or increase its kinase activity. They can achieve this by stabilizing Clb1 in its active form, enhancing its binding affinity to the CDK, or by altering the conformation of the CDK in such a way that its catalytic activity is increased. Such activators are typically small molecules that have been carefully crafted through an understanding of Clb1's structure and its interaction with the CDK.
The detailed study of Clb1 activators involves an extensive examination of the molecular dynamics between Clb1 and its CDK partner. Techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy can provide structural insights into how these activators interact with Clb1 at an atomic level. These structural insights are pivotal for the rational design of molecules that can specifically target and activate Clb1. Computational chemistry and molecular modeling are also integral to this process, allowing scientists to simulate the interaction between Clb1 and potential activators and to predict the efficacy of novel compounds before they are synthesized in the laboratory.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Purvalanol B | 212844-54-7 | sc-361300 sc-361300A | 10 mg 50 mg | $199.00 $846.00 | ||
Purvalanol A is a selective inhibitor of CDKs. By inhibiting competing CDKs that do not interact with Clb1, it can enhance the relative activity of the Clb1-CDK complex, thus promoting cell cycle progression phases that Clb1 regulates. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a CDK inhibitor that preferentially targets certain CDKs. Its action can lead to a relative increase in Clb1-CDK complexes activity by reducing the activity of other CDKs that regulate different phases of the cell cycle. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor with the potential to indirectly enhance Clb1's function by decreasing the activity of non-Clb1-associated CDKs, thus modulating cell cycle transitions in favor of those controlled by Clb1. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $77.00 $179.00 | 18 | |
Mevastatin inhibits HMG-CoA reductase, leading to decreased cholesterol synthesis and potentially increased availability of IPP for prenylation, indirectly enhancing Clb1-CDK complex stability and activity. | ||||||
Geranylgeranylpyrophosphate triammonium salt | 6699-20-3 | sc-200849 | 200 µg | $122.00 | ||
GGPP is another prenyl donor and could influence the activity of Clb1 by stabilizing interacting proteins through prenylation, thus facilitating Clb1's role in the cell cycle. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride can inhibit glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 may stabilize proteins that are positive regulators of Clb1-CDK complexes, indirectly enhancing Clb1 activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
TSA is a histone deacetylase inhibitor that can lead to hyperacetylation of histones and affect gene expression. This may result in the upregulation of genes encoding proteins that positively regulate the Clb1-CDK complex. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels, which activates PKA. PKA can phosphorylate proteins that regulate the cell cycle and potentially increase Clb1-CDK complex activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of cyclins and CDK inhibitors. By stabilizing these molecules, it may indirectly enhance Clb1's associated CDK activity by altering the balance of cell cycle regulators. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Sodium orthovanadate is a phosphatase inhibitor which can lead to increased phosphorylation levels of cell cycle regulators. This increased phosphorylation could enhance Clb1-CDK complex activity indirectly. | ||||||